Please note that for any urgent or life-threatening conditions, we always recommend that you should call 999 or go to your nearest emergency department immediately. We are usually able to provide face to face or remote appointments with our GP’s within 24 hours. Please contact 01442 331 900 to book an appointment.
Dr Nik Kamperidis is a leading consultant gastroenterologist with special interest in inflammatory bowel disease, endoscopy, colonoscopy, indigestion,irritable bowel syndrome and the impact of diet on symptoms and diseases of the digestive tract.
Dr Kamperidis graduated from the Aristotle University in Greece in 2003. He undertook his specialist training in London and Kent, and in Surrey and Sussex, as well as an advanced endoscopy fellowship at St Mark’s Hospital. Dr Kamperidis completed his postgraduate studies and was awarded an MSc degree and an MD (Res) from Barts and the London School of Medicine.
His thesis Nutrient Effects in Inflammatory Bowel Disease has been presented at national and international conferences and his research is published in peer-reviewed journals. His current research focuses on treatment optimisation of novel therapies and the improvement in quality care for patients who have IBD.
Dr Kamperidis always adopts a patient centred approach in investigating and treating different conditions. He is calm and approachable and eager to spend time in listening and understanding patient’s needs and views.
In his free time, he enjoys meeting friends and listening to classical music.
He speaks Greek and French (Basic) in addition to English.
1. Impact of Therapeutic Drug level monitoring on outcomes of patients with Crohn’s Disease treated with Infliximab: real world data from a retrospective single centre cohort study.
N Kamperidis, P Middleton, T Tyrrell, I Stasinos, N Arebi
Frontline Gastroetnerology, 2019
2. Monitoring of biologics in Inflammatory Bowel Disease (IBD) patients using the Patients Know Best electronic portal: Pilot study of update, acceptability and outcomes.
N Kamperidis, M O’Connor, N Arebi
Gastrointestinal Nursing, 2018
3. Effectiveness and safety of Vedolizumab in anti-TNF naïve patients with Iinflammatory Bowel Disease – A multicentre retrospective European study.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M
Inflammatory Bowel Disease, 2018
4. The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery.
Kamperidis N, Faiz O, Arebi N.
Annals of Surgery, 2017
5. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease.
Goodhand JR, Kamperidis N, Sirwan B, Macken L, Tshuma N, Koodun Y, Chowdhury FA, Croft NM, Direkze N, Langmead L, Irving PM, Rampton DS, Lindsay JO.
Alimentary Pharmacology Therapeutics, 2013
6. The phenotype and course of inflammatory bowel disease in UK patients of Bangladeshi descent.
Goodhand JR, Kamperidis N, Joshi NM, Wahed M, Koodun Y, Cantor EJ, Croft NM, Langmead FL,Lindsay JO, Rampton DS.
Alimentary Pharmacology Therapeutics, 2012
7. Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory Bowel disease.
Kamperidis N, Goodhand JR, Chowdhury FA, Koodun Y, Direzke NC, Naik S, Sanderson IR, Croft NM, Langmead FL, Irving PM, Rampton DS, Lindsay JO.
Journal of Pediatric Gastroenterology and Nutrition, 2012
8. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease.
Goodhand JR, Kamperidis N, Rao A, Laskaratos F, McDermott A, Wahed M, Naik S, Croft NM, Lindsay JO, Sanderson IR, Rampton DS.
Inflamm Bowel Dis. 2012
9. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis.
Goodhand JR, Kamperidis N, Nguyen
